Shinya Sakurai
Nara Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shinya Sakurai.
Journal of Hepatology | 2001
Hideyuki Kojima; Shinya Sakurai; Shigeki Kuriyama; Hitoshi Yoshiji; Hiroo Imazu; Masahito Uemura; Yoshihiro Nakatani; Jyunichi Yamao; Hiroshi Fukui
BACKGROUND/AIMS Endothelin-1 has been suggested to play a key role in cirrhotic portal hypertension, but a role of its receptors in vivo is not fully elucidated. METHODS Biliary cirrhosis was induced by bile duct ligation. Expressions of endothelin-1 and its receptors were evaluated by radioimmunoassay and/or reverse-transcription polymerase chain reaction. Hemodynamics were studied using endothelin receptor agonist or antagonist. RESULTS Portal pressure and hepatic endothelin-1 concentrations progressively increased in parallel after bile duct ligation. Gene expression of hepatic prepro-endothelin-1 and endothelin B receptor enhanced after bile duct ligation, while that of endothelin A receptor was unchanged. Intraportal administration of endothelin-1 or endothelin B receptor agonist sarafotoxin 6c (0.5 nmol/kg, respectively) progressively raised portal pressure in both sham and cirrhotic rats. Portal hypertensive effect of sarafotoxin 6c was more intense in cirrhotic rats than sham animals. Neither endothelin A receptor antagonist FR139317 (1 mg/kg) nor endothelin B receptor antagonist BQ788 (1 mg/kg) alone ameliorated cirrhotic portal hypertension. Only the combined endothelin A and B blockade was associated with a decrease in portal pressure in cirrhotic rats. CONCLUSIONS These results indicate that endothelin-1 plays a major role in cirrhotic portal hypertension through endothelin receptor subtype B together with subtype A in vivo.
Journal of Gastroenterology | 2002
Hideyuki Kojima; Masahito Uemura; Shinya Sakurai; Tatsuichi Ann; Yoshinobu Ishii; Hiroo Imazu; Masahide Yoshikawa; Kunio Ichijima; Hiroshi Fukui
Background:Background: Liver disturbance in rheumatoid diseases results not only from liver disease associated with the rheumatoid diseases themselves but also from various other causes. This study aimed to elucidate the clinical features of liver disturbance in rheumatoid diseases, focusing on the cause of this disturbance. Methods: A clinicopathological study was performed in 306 patients (106 with systemic lupus erythematosus, 71 with Sjögrens syndrome, 59 with rheumatoid arthritis, 27 with scleroderma, 30 with polymyositis, and 13 with polyarteritis nodosa). Results: Liver disturbance occurred in 43% of these patients and resulted from various causes. Its degree and duration varied from one cause to another. Liver disease associated with rheumatoid diseases was the leading cause of the liver disturbance in these patients and was characterized by mild and transient liver disturbance (maximum alanine aminotransferase [ALT] level during the study period, 68 ± 8 IU/ml; maximum alkaline phosphatase [ALP] level, 410 ± 31 IU/ml; duration of liver disturbance, 6 ± 2 months). Most patients with this type of liver disease showed minimal change in liver histology, although two-thirds of those evaluated by the international scoring system for autoimmune hepatitis (AIH) were classified as “probable” or “definite”. Eight of 14 patients with histologically proven chronic hepatitis or cirrhosis were infected with hepatotropic virus (7 with hepatitis C virus [HCV] and 1 with hepatitis B virus [HBV]). Five of 9 patients in whom the hepatic lesion progressed had hepatotropic virus infection (4 with HCV and 1 with HBV), and the other 4 patients suffered from autoimmune liver diseases. Conclusions: Liver disease associated with rheumatoid diseases was the leading cause of liver disturbance in these patients and was characterized by mild and transient liver disturbance, whereas progressive liver diseases were often associated with hepatotropic virus, mainly HCV, or autoimmune liver diseases. Liver histology is indispensable for differentiating AIH from liver disease associated with rheumatoid diseases.
Journal of Gastroenterology and Hepatology | 2008
Hideyuki Kojima; Shinya Sakurai; Masahito Uemura; Kensuke Kitamura; Hiroki Kanno; Yoshiyuki Nakai; Hiroshi Fukui
Background and Aim: Endocytic retrieval of multidrug resistance protein 2 (MRP2) is closely associated with cholestasis and may be attributed to the disturbed linking of MRP2 and radixin, a cross‐linker between actin filaments and membrane proteins. This study aimed to investigate the role of radixin in the altered localization of MRP2 in various human cholestatic liver diseases.
Hepatology Research | 2007
Hideyuki Kojima; Shinya Sakurai; Hitoshi Yoshiji; Masahito Uemura; Masahide Yoshikawa; Hiroshi Fukui
Aim: Cholestasis has been associated with the endocytic retrieval of multidrug resistance protein 2 (Mrp2), but its mechanism is still unclear. Recent studies have indicated that radixin, a cross‐linker between the actin filaments and membrane proteins, may be activated by phosphorylation and may be required for the canalicular localization of Mrp2.
Alcoholism: Clinical and Experimental Research | 1999
Masao Fujimoto; Masahito Uemura; Hideyuki Kojima; Yoshinobu Ishii; Tatsuichi Ann; Shinya Sakurai; Kouji Okuda; Ryuichi Noguchi; Satoshi Adachi; Hiroyuki Kitano; Kazushige Hoppo; Tadashi Higashino; Akira Takaya; Hiroshi Fukui
Severe alcoholic liver injury has been relatively rare, but is gradually increasing in Japan. The clinical features and prognostic factors in severe alcoholic liver injury were retrospectively investigated in 105 patients, consisting of 3 with severe alcoholic hepatitis (SAH), 43 with cirrhosis with superimposed alcoholic hepatitis [liver cirrhosis (LC) +alcoholic hepatitis (AH)], 38 with AH, and 21 with alcoholic cirrhosis. Seven of the 105 patients (6.7%, 2 with SAH and 5 with LC+AH) died of hepatic failure. Patients with SAH showed severe hyperbilirubinemia, reduced hepatic biosynthetic capacity, and marked acute inflammatory reactions, and developed multiple organ failure, such as disseminated intravascular coagulation (DIC), renal failure, acute pancreatitis, or pneumonia. Two SAH patients died within 1 month, whereas five with LC+AH died within 77 days during the second episode of AH. In these nonsurvivors, the serum total bilirubin (T.Bil) level was not normalized, and the hepaplastin test (HPT), serum albumin, cholesterol, and platelet count were not markedly improved after the first episode of AH. In the survivors, elevation of AST lasted longer, and the improvement of T.Bil, hepatic biosynthetic capacity, and the platelet count were much less in patients with LC+AH than in those with AH. Multivariate analysis using the Cox proportional hazards model showed serum C-reactive protein (CRP) and DIC as significant independent prognostic factors among SAH, LC+AH, and AH groups. When factors related to multiple organ failure, such as DIC and renal failure, were excluded, T.Bil and CRP were selected as independent prognostic factors. In patients with LC+AH and AH, CRP, and HPT were shown to be significant independent prognostic factors. These results suggest that SAH with multiple organ failure, and another episode of AH in advanced LC with hyperbilirubinemia and reduced hepatic biosynthetic capacity, are indicative of an extremely poor prognosis in chronic alcoholics.
Scandinavian Journal of Gastroenterology | 2004
Hideyuki Kojima; Shinya Sakurai; Masato Uemura; H. Satoh; T. Nakashima; N. Minamino; Kenji Kangawa; H. Matsuo; Hiroshi Fukui
Background: Plasma levels of adrenomedullin, a potent vasodilator peptide, are increased in cirrhotic patients, whereas its role in vascular hyporeactivity in cirrhosis has not been clarified. Methods: Adrenomedullin expression was evaluated by radioimmunoassay and reverse‐transcription polymerase chain reaction. Vascular reactivity to phenylephrine, α 1 ‐adrenoceptor agonist, was investigated in the aortic rings from control rats and CCl 4 ‐induced cirrhotic rats with ascites in the presence of the neutralizing antibody against adrenomedullin, human adrenomedullin and/or N G ‐nitro‐L‐arginine methyl ester, a nitric oxide synthase inhibitor. Results: Plasma adrenomedullin levels were significantly higher in cirrhotic rats than in controls (16.3 ± 2.9 versus 7.4 ± 1.7 fmol/mL, P < 0.05) and correlated negatively with systemic arterial pressure (r = −0.62, P < 0.05). Gene expression of adrenomedullin in various organs (liver, kidney, lung) and vessels (portal vein, aorta) was enhanced in cirrhotic rats compared with controls. Neutralizing antibody against adrenomedullin ameliorated the blunted contractile response to phenylephrine in cirrhotic aorta (Rmax: 1.5 ± 0.1 versus 1.0 ± 0.1 g/mg tissue, P < 0.05), whereas contraction remained unchanged in control aorta (Rmax: 1.9 ± 0.2 versus 1.9 ± 0.2 g/mg tissue). Intravenous infusion of human adrenomedullin induced a reduction of mean arterial pressure together with an increase of serum nitrate levels, which was abolished by neutralizing antibody against adrenomedullin. Human adrenomedullin caused a blunted contractile response to phenylephrine in both control and cirrhotic aortas, which was not observed in the presence of N G ‐nitro‐L‐arginine methyl ester. Conclusions: These findings indicate that the overproduction of adrenomedullin may contribute to vascular hyporeactivity in cirrhosis via a release of nitric oxide.
Indian Journal of Gastroenterology | 2009
Tatsuhiro Tsujimoto; Hisao Fujii; Hideto Kawaratani; Shinya Sakurai; Hideyuki Kojima; Hiroshi Fukui
Endoscopic retrieval of foreign bodies is sometimes a challenging task. We report a case of simultaneous removal of 5 coins from the stomach without causing mucosal injury using a specially-designed devices consisting of retrieval net, endoscopic attachment balloon and a disposable tip attachment. This technique has not been described before.
Alcoholism: Clinical and Experimental Research | 2000
Masao Fujimoto; Masahito Uemura; Yoshihiro Nakatani; S. Tsujita; Kazushige Hoppo; T. Tamagawa; Hiroyuki Kitano; Masaji Kikukawa; Tatsuichi Ann; Yoshinobu Ishii; Hideyuki Kojima; Shinya Sakurai; R. Tanaka; T. Namisaki; Ryuichi Noguchi; Tadashi Higashino; Eiryou Kikuchi; K. Nishimura; Akira Takaya; Hiroshi Fukui
Alcoholism: Clinical and Experimental Research | 2007
Hideyuki Kojima; Shinya Sakurai; Masahito Uemura; Hiroshi Fukui; Hiroyo Morimoto; Yasuhiro Tamagawa
Journal of Hepatology | 2006
Tadashi Namisaki; Hitoshi Yoshiji; Hideyuki Kojima; Junichi Yoshii; Yasuhide Ikenaka; Ryuichi Noguchi; Shinya Sakurai; Koji Yanase; Mitsuteru Kitade; Masaharu Yamazaki; Kiyoshi Asada; Masahito Uemura; Mitsutoshi Nakamura; Hiroshi Fukui